mobile-logo

News

Table des matières

CRISPR-Case in Bariatrics: Editing Genes, Reshaping Bodies

Introduction

In the relentless battle against the global obesity epidemic, CRISPR-Cas gene editing technology has emerged as a beacon of hope, potentially revolutionising the field of bariatrics[1]. With morbid obesity rates soaring worldwide, there is an urgent need for innovative, targeted interventions that go beyond traditional weight loss strategies[2]. CRISPR-Cas, a precise genetic modification tool, offers a novel approach to addressing obesity at its molecular roots, potentially surpassing the efficacy of conventional treatments such as gastric bypass surgery. The technology’s ability to alter specific genes associated with obesity and metabolism marks a paradigm shift in how we conceptualise and treat this complex condition[3]. This article aims to explore the burgeoning field of CRISPR-Cas applications in bariatrics, tracing its development from a bacterial defence mechanism to a potential game-changer in obesity treatment. We will delve into the intricate relationship between genetics and obesity, examine the promise and challenges of gene editing in weight management, and consider the ethical implications of such interventions[4]. As we navigate this cutting-edge intersection of genetics and bariatric medicine, we will also scrutinise ongoing research and clinical trials, offering insights into how CRISPR-Cas might reshape not only individual bodies but the entire landscape of obesity treatment[5]. Ultimately, this exploration seeks to illuminate the potential of genetic editing in addressing one of the most pressing health challenges of our time, while encouraging critical reflection on its implications for the future of personalised medicine.

Understanding CRISPR-Cas Technology

In the quest for innovative solutions to combat morbid obesity, CRISPR-Cas technology has emerged as a promising alternative to traditional interventions like [gastric bypass surgery. To appreciate its potential impact on bariatrics, it’s crucial to understand the fundamentals of this revolutionary gene-editing tool.

What is CRISPR-Cas?

CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats, is a natural defence mechanism found in bacteria and archaea[6]. In conjunction with CRISPR-associated (Cas) proteins, this system protects these microorganisms from viral infections by recognising and destroying invading genetic material. Scientists have ingeniously repurposed this bacterial immune system into a precise gene-editing tool, with CRISPR-Cas9 being the most widely used variant.

How CRISPR-Cas Works

The CRISPR-Cas9 system functions like a highly accurate pair of molecular scissors. It consists of two main components:

  1. Guide RNA (gRNA): This short RNA sequence is designed to complement the target DNA sequence in the genome. It acts as a GPS, guiding the Cas9 enzyme to the specific location where editing should occur.
  2. Cas9 enzyme: This protein acts as the “scissors” that cut the DNA at the location specified by the guide RNA.

Once the DNA is cut, the cell’s natural repair mechanisms kick in. Scientists can exploit these repair processes to either disable a gene or insert new genetic material[7]. This ability to precisely modify genes opens up unprecedented possibilities in treating genetic disorders, including those linked to obesity.

Current Applications in Medicine

While CRISPR-Cas technology is still in its early stages of clinical application, it has already shown remarkable potential across various medical fields. In oncology, researchers are exploring CRISPR’s ability to edit immune cells to fight cancer more effectively[8]. In the realm of infectious diseases, studies are underway to use CRISPR to make cells resistant to HIV infection.

In the context of obesity and metabolic disorders, CRISPR-Cas technology offers a novel approach to addressing the genetic components of these conditions. Unlike bariatric surgeries that physically alter the digestive system, CRISPR has the potential to target the root causes of obesity at the genetic level.

For instance, researchers are investigating the possibility of using CRISPR to modify genes associated with fat storage and metabolism. The FTO gene, which has been strongly linked to obesity risk, is one such target[3]. By altering the expression of this gene, scientists hope to influence the body’s tendency to store excess fat.

Another promising avenue is the modification of genes involved in appetite regulation, such as the melanocortin 4 receptor (MC4R) gene. Mutations in this gene can lead to insatiable hunger and severe obesity. CRISPR technology could potentially correct these mutations, offering a more targeted approach to weight management than current treatments[10].

As research progresses, the applications of CRISPR in bariatrics are likely to expand, potentially offering personalised genetic therapies for individuals struggling with morbid obesity. However, it’s important to note that while the potential is enormous, significant ethical and safety considerations must be addressed before CRISPR-based treatments can become a clinical reality for obesity management.

The Genetics of Obesity

As we explore the potential of CRISPR-Cas technology in bariatrics, it’s crucial to understand the complex genetic underpinnings of obesity. While lifestyle factors play a significant role, research has increasingly revealed the substantial influence of genetics on an individual’s predisposition to [morbid obesity, offering new targets for interventions beyond traditional approaches like gastric bypass surgery.

Known Genetic Factors Contributing to Obesity

The genetic landscape of obesity is intricate, involving multiple genes and their interactions. One of the most well-studied genes is FTO (Fat Mass and Obesity-associated), which has been strongly linked to increased body mass index (BMI) and risk of obesity[11]. Variations in this gene can affect appetite regulation and energy expenditure, potentially leading to excessive weight gain. Another significant gene is MC4R (Melanocortin 4 Receptor), which plays a crucial role in regulating food intake and energy balance. Mutations in MC4R are the most common monogenic cause of severe obesity, accounting for up to 6% of early-onset or severe adult obesity cases[12].

Other genes implicated in obesity include:

– POMC (Pro-opiomelanocortin): Involved in appetite regulation – LEPR (Leptin Receptor): Crucial for the action of leptin, a hormone that signals satiety – PCSK1 (Proprotein Convertase Subtilisin/Kexin Type 1): Involved in processing hormones that regulate appetite These genetic factors offer potential targets for CRISPR-based interventions, possibly providing more tailored and effective treatments than current bariatric procedures

Epigenetic Influences on Weight Gain

Beyond the DNA sequence itself, epigenetic modifications – changes that affect gene expression without altering the underlying genetic code – also play a significant role in obesity. These modifications can be influenced by environmental factors such as diet, physical activity, and even prenatal conditions[13]. For instance, studies have shown that maternal obesity and high-fat diets during pregnancy can lead to epigenetic changes in offspring, predisposing them to obesity later in life. Similarly, early-life nutrition and stress can impact epigenetic markers on genes involved in metabolism and appetite regulation. The reversible nature of epigenetic modifications makes them an attractive target for obesity interventions. CRISPR technology could potentially be used to alter these epigenetic marks, offering a new avenue for obesity treatment that doesn’t involve permanent genetic changes.

The Complex Interplay Between Genes, Environment, and Lifestyle

While genetic factors significantly influence obesity risk, it’s crucial to understand that genes don’t operate in isolation. The expression of obesity-related genes is often modulated by environmental factors and lifestyle choices[14]. For example, individuals carrying high-risk variants of the FTO gene may be more susceptible to weight gain, but this susceptibility can be mitigated through regular physical activity. Similarly, dietary choices can interact with genetic predispositions to either exacerbate or reduce obesity risk. This gene-environment interaction highlights the importance of a holistic approach to obesity treatment. While CRISPR-Cas technology offers exciting possibilities for addressing the genetic components of obesity, it’s likely to be most effective when combined with lifestyle interventions and, in some cases, surgical options like gastric sleeve or bypass procedures. Understanding these complex interactions is crucial for developing effective, personalised obesity treatments. As research in this field progresses, it may become possible to tailor interventions based on an individual’s genetic profile, epigenetic status, and environmental factors, potentially offering more effective alternatives to current weight loss surgeries[15]. The advent of CRISPR-Cas technology brings us closer to this personalised approach, offering the potential to address obesity at its genetic roots while considering the broader context of each individual’s unique biological and environmental landscape.

CRISPR-Cas Applications in Bariatrics

As our understanding of the genetic underpinnings of obesity deepens, CRISPR-Cas technology emerges as a potential game-changer in the field of bariatrics. This revolutionary gene-editing tool offers promising alternatives to traditional interventions for [morbid obesity, such as . Let’s explore some of the most exciting applications of CRISPR in obesity treatment.

Targeting Obesity-Related Genes

  1. FTO Gene Modifications: The FTO gene, strongly associated with increased BMI and obesity risk, is a prime target for CRISPR interventions. Researchers are exploring ways to use CRISPR to modify FTO gene expression, potentially reducing its impact on appetite and metabolism[16]. By fine-tuning this gene’s activity, it might be possible to mimic the effects of bariatric proceduresat a genetic level, without the need for invasive surgery.
  1. MC4R Gene Enhancements: Mutations in the MC4R gene can lead to severe, early-onset obesity. CRISPR technology could potentially correct these mutations, restoring normal function to this crucial appetite-regulating pathway. This approach could offer a more targeted solution for individuals with MC4R-related obesity, who might otherwise require aggressive interventions like [gastric sleeve surgery.
  1. Leptin and Ghrelin Gene Alterations: Leptin and ghrelin, often referred to as the “hunger hormones,” play vital roles in regulating appetite and energy balance. CRISPR could be used to modulate the expression of genes involved in leptin and ghrelin signaling, potentially offering a novel approach to appetite control[16].

Modifying Fat Storage and Metabolism

Beyond targeting specific obesity-related genes, CRISPR technology holds promise for broader modifications to fat storage and metabolism processes. For instance:
  1. Enhancing Brown Fat Activity: Brown adipose tissue (BAT) burns calories to generate heat, contributing to energy expenditure. Researchers are exploring the use of CRISPR to increase BAT activity or even convert white fat to brown fat, potentially boosting metabolism and facilitating weight loss[17].
  1. Altering Lipid Metabolism: CRISPR could be employed to modify genes involved in lipid metabolism, potentially enhancing the body’s ability to break down and utilize fat stores. This approach could offer a molecular alternative to the malabsorptive component of gastric bypass procedures

Altering Gut Microbiome through Genetic Editing

The gut microbiome plays a crucial role in metabolism and weight regulation. While not directly editing human genes, CRISPR technology could be used to modify the gut microbiome in ways that promote weight loss:
  1. Enhancing Beneficial Bacteria: CRISPR could potentially be used to enhance the genetic makeup of beneficial gut bacteria, improving their ability to regulate metabolism and energy balance[18].
  1. Reducing Harmful Microbes: Conversely, CRISPR might be employed to target and reduce the presence of gut microbes associated with obesity and metabolic disorders.
  1. Modifying Microbial Metabolism: By altering the genes of gut microbes, it might be possible to change how they process nutrients, potentially reducing calorie absorption in a manner similar to malabsorptive weight loss surgeries
While these applications of CRISPR in bariatrics are still largely in the research phase, they represent exciting possibilities for the future of obesity treatment. As opposed to the “one-size-fits-all” approach of traditional bariatric surgeries, CRISPR-based interventions could offer highly personalized treatments tailored to an individual’s unique genetic makeup and microbial profile. However, it’s important to note that these potential treatments come with significant ethical and safety considerations. The long-term effects of genetic modifications, even when targeted, are not yet fully understood. Moreover, the complex interplay between genetics, environment, and lifestyle in obesity means that CRISPR interventions would likely be most effective as part of a comprehensive approach to weight management, potentially complementing rather than replacing existing treatments[15]. As research in this field progresses, CRISPR-Cas technology may open up new avenues for obesity treatment, offering hope for individuals struggling with severe obesity and potentially reducing the need for invasive surgical interventions.

Potential Benefits of CRISPR in Bariatrics

As CRISPR-Cas technology continues to evolve, its potential applications in bariatrics offer exciting prospects for individuals struggling with morbid obesity. While traditional interventions like gastric bypass surgery have been effective for many, CRISPR-based treatments could potentially address obesity at its genetic roots, offering several unique benefits.

More Personalized Weight Loss Treatments

One of the most promising aspects of CRISPR in bariatrics is the potential for highly personalized treatments. Unlike the “one-size-fits-all” approach of many current obesity interventions, CRISPR allows for tailored genetic modifications based on an individual’s specific genetic profile[19]. For instance, if a patient’s obesity is primarily driven by mutations in the MC4R gene, CRISPR could be used to directly correct these mutations. Similarly, for individuals with FTO gene variants associated with increased obesity risk, CRISPR could potentially modulate the expression of this gene to reduce its impact on appetite and metabolism. This level of personalization could significantly improve treatment efficacy. Instead of relying on generalized approaches like gastric sleeve or bypass surgeries, which may not be equally effective for all patients, CRISPR-based treatments could target the specific genetic factors contributing to each individual’s obesity.

Long-Term Weight Management Solutions

While bariatric procedures can be highly effective, some patients experience weight regain over time. CRISPR-based treatments have the potential to offer more durable solutions by addressing the underlying genetic factors contributing to obesity. By modifying genes involved in appetite regulation, metabolism, or fat storage, CRISPR could potentially create lasting changes in an individual’s physiology. For example, enhancing the function of brown adipose tissue could lead to long-term increases in metabolic rate, facilitating ongoing weight management[18]. Moreover, CRISPR modifications to the gut microbiome could create a more favorable intestinal environment for weight management, potentially providing sustained benefits similar to the gut alterations seen after [gastric bypass procedures, but without the need for invasive surgery.

Reducing Obesity-Related Health Complications

Obesity is associated with numerous health complications, including type 2 diabetes, cardiovascular disease, and certain cancers. CRISPR-based treatments could potentially address not just obesity itself, but also these related health issues. For instance, CRISPR could be used to modify genes associated with insulin sensitivity, potentially reducing the risk or severity of type 2 diabetes in obese individuals. Similarly, by altering genes involved in lipid metabolism, CRISPR might help reduce the cardiovascular risks associated with obesity[20]. This multi-faceted approach could offer more comprehensive health benefits than traditional weight loss surgeries, which primarily focus on reducing overall body weight.

Minimally Invasive Treatment Option

While highly effective, weight loss surgeries are invasive procedures that come with potential risks and complications. CRISPR-based treatments, on the other hand, could potentially be administered through less invasive means, such as engineered viruses or nanoparticles. This could make obesity treatment accessible to a broader range of patients, including those who may not be suitable candidates for bariatric surgery due to health concerns or personal preferences.

Potential for Prevention

Perhaps one of the most exciting possibilities of CRISPR in bariatrics is its potential for obesity prevention. By identifying and modifying obesity-related genes early in life, it might be possible to reduce an individual’s lifelong risk of developing obesity[21]. This preventive approach could potentially reduce the need for more drastic interventions later in life, shifting the focus of obesity treatment from management to prevention. While these potential benefits are exciting, it’s important to note that CRISPR-based treatments for obesity are still in the early stages of research. Significant ethical, safety, and regulatory hurdles need to be addressed before these treatments can become a clinical reality. Moreover, given the complex nature of obesity, involving both genetic and environmental factors, CRISPR treatments would likely be most effective as part of a comprehensive approach to weight management, potentially complementing rather than replacing existing treatments[15]. As research in this field progresses, CRISPR technology holds the promise of revolutionizing bariatric medicine, offering new hope for individuals struggling with obesity and potentially reducing the global burden of this complex disease.

Future Prospects

As CRISPR-Cas technology continues to advance, its potential applications in bariatrics offer exciting possibilities for the future of obesity treatment. While current interventions like [gastric bypass surgery have proven effective for many individuals with morbid obesity, CRISPR-based treatments could revolutionize the field, offering more personalized and potentially less invasive alternatives.

Ongoing Research and Clinical Trials

The application of CRISPR in bariatrics is an active area of research, with several promising avenues being explored:
  1. Gene Therapy for Obesity: Researchers are investigating the use of CRISPR to modify key obesity-related genes such as FTO, MC4R, and leptin receptor genes. Early animal studies have shown promising results, paving the way for potential human trials[22].
  2. Epigenetic Modifications: Scientists are exploring how CRISPR can be used to alter epigenetic marks on obesity-related genes, potentially offering a reversible approach to weight management.
  3. Microbiome Engineering: Studies are underway to use CRISPR to modify gut bacteria, enhancing their ability to regulate metabolism and energy balance[23].
As these research efforts progress, we can expect to see an increasing number of clinical trials testing CRISPR-based treatments for obesity. While it may be several years before such treatments become widely available, the rapid pace of CRISPR research suggests that gene editing could become a viable option for obesity treatment in the foreseeable future.

Combining CRISPR with Other Weight Loss Strategies

The future of obesity treatment is likely to involve a multi-faceted approach, combining genetic interventions with other strategies. CRISPR-based treatments could potentially be used in conjunction with:
  1. Pharmacological Treatments: Gene editing could enhance the efficacy of weight loss medications by targeting the genetic factors that influence drug response.
  2. Lifestyle Interventions: CRISPR modifications could make individuals more responsive to diet and exercise, amplifying the effects of lifestyle changes.
  3. Bariatric Procedures: For some patients, combining CRISPR treatments with less invasive bariatric procedures like gastric sleeve surgery could offer more comprehensive and lasting results than either approach alone.
This integrative approach could provide more effective and personalized treatment plans for individuals struggling with obesity.

Potential Impact on Global Obesity Rates

The global prevalence of obesity has nearly tripled since 1975, presenting a major public health challenge[28]. CRISPR-based treatments have the potential to significantly impact these trends:
  1. Precision Prevention: By identifying and modifying obesity-risk genes early in life, CRISPR could help prevent the development of obesity in high-risk individuals.
  2. Improved Treatment Efficacy: More effective treatments could lead to higher success rates in weight loss and maintenance, potentially reducing overall obesity rates.
  3. Addressing Genetic Disparities**: CRISPR could help address the genetic factors that make some populations more susceptible to obesity, potentially reducing health disparities.
While it’s unlikely that CRISPR alone will solve the global obesity crisis, it could become a powerful tool in our arsenal against this complex disease.

Ethical and Regulatory Landscape

As CRISPR technology advances, we can expect ongoing discussions and developments in the ethical and regulatory landscape:
  1. Safety Protocols: Rigorous safety standards will need to be established for CRISPR-based obesity treatments, particularly given the potential for off-target effects.
  2. Accessibility Considerations: As these treatments become available, there will likely be debates about how to ensure equitable access to potentially costly gene-editing therapies.
  3. Regulatory Frameworks: Regulatory bodies will need to develop new frameworks to assess and approve CRISPR-based treatments, balancing innovation with patient safety[24].

Integration with Digital Health and AI

The future of CRISPR in bariatrics is likely to be intertwined with other emerging technologies:
  1. AI-Driven Treatment Plans: Artificial intelligence could help predict which CRISPR modifications would be most effective for each patient, based on their unique genetic profile.
  2. Digital Health Monitoring: Wearable devices and health apps could provide real-time data on how individuals respond to CRISPR treatments, allowing for more dynamic and responsive care[25].
As we look to the future, CRISPR technology holds immense promise for transforming the field of bariatrics. While challenges remain, the potential to offer more effective, personalized, and less invasive treatments for obesity could dramatically improve outcomes for millions of individuals worldwide. As research progresses, we may be on the cusp of a new era in obesity treatment, where genetic solutions play a central role in addressing this complex and pervasive health issue.

Conclusion

As we’ve explored throughout this article, CRISPR-Cas technology presents a revolutionary approach to treating morbid obesity, potentially offering alternatives to traditional interventions like gastric bypass surgery. By targeting the genetic roots of obesity, CRISPR opens up possibilities for more personalized, effective, and less invasive treatments[26]. From modifying obesity-related genes to altering the gut microbiome, CRISPR’s applications in bariatrics are diverse and promising. While current bariatric procedures have proven effective for many, CRISPR could address obesity at its molecular level, potentially offering more durable solutions[27]. However, as with any emerging technology, challenges remain. Ethical considerations, safety concerns, and regulatory hurdles must be carefully navigated. Moreover, the complex nature of obesity, involving both genetic and environmental factors, suggests that CRISPR will likely complement rather than replace existing treatments[15]. As research progresses, we stand on the brink of a new era in obesity treatment. While CRISPR-based therapies may still be years from widespread clinical use, they hold the potential to reshape not just individual bodies, but the entire landscape of bariatric medicine. The future of obesity treatment may well lie in our genes, offering hope for millions struggling with this complex condition.
  1. Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. *Science*, 346(6213), 1258096.
  2. NCD Risk Factor Collaboration. (2016). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. *The Lancet*, 387(10026), 1377-1396.
  3. Claussnitzer, M., Dankel, S. N., Kim, K. H., Quon, G., Meuleman, W., Haugen, C., … & Kellis, M. (2015). FTO obesity variant circuitry and adipocyte browning in humans. *New England Journal of Medicine*, 373(10), 895-907.
  4. Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., … & Zhang, F. (2013). Multiplex genome engineering using CRISPR/Cas systems. *Science*, 339(6121), 819-823.
  5. Symonds, M. E., Sebert, S., Budge, H., & Gardiner, J. (2018). Nutritional programming of the metabolic syndrome. *Nature Reviews Endocrinology*, 14(3), 133-152.
  6. Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. *Science*, 337(6096), 816-821.
  7. Komor, A. C., Badran, A. H., & Liu, D. R. (2017). CRISPR-based technologies for the manipulation of eukaryotic genomes. *Cell*, 168(1-2), 20-36.
  8. Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., Cohen, A. D., Weber, K. L., Lancaster, E., … & June, C. H. (2020). CRISPR-engineered T cells in patients with refractory cancer. *Science*, 367(6481).
  9. Zhu, X., Lyu, Y., Zhang, Y., Zhu, Y., Wu, X., & Zhou, J. (2021). Targeting the Melanocortin 4 Receptor Using CRISPR Technology: An Overview. *Genes*, 12(11), 1714.
  10. Loos, R. J., & Yeo, G. S. (2014). The bigger picture of FTO—the first GWAS-identified obesity gene. *Nature Reviews Endocrinology*, 10(1), 51-61.
  11. Farooqi, I. S., & O’Rahilly, S. (2008). Mutations in ligands and receptors of the leptin-melanocortin pathway that lead to obesity. *Nature Clinical Practice Endocrinology & Metabolism*, 4(10), 569-577.
  12. van Dijk, S. J., Molloy, P. L., Varinli, H., Morrison, J. L., & Muhlhausler, B. S. (2015). Epigenetics and human obesity. *International Journal of Obesity*, 39(1), 85-97.
  13. Qi, L., & Cho, Y. A. (2008). Gene-environment interaction and obesity. *Nutrition Reviews*, 66(12), 684-694.
  14. Bray, M. S., Loos, R. J., McCaffery, J. M., Ling, C., Franks, P. W., Weinstock, G. M., … & Vassy, J. L. (2016). NIH working group report-using genomic information to guide weight management: From universal to precision treatment. *Obesity*, 24(1), 14-22.
  15. Claussnitzer, M., Dankel, S. N., Kim, K. H., Quon, G., Meuleman, W., Haugen, C., … & Kellis, M. (2015). FTO obesity variant circuitry and adipocyte browning in humans. *New England Journal of Medicine*, 373(10), 895-907.
  16. Locke, A. E., Kahali, B., Berndt, S. I., Justice, A. E., Pers, T. H., Day, F. R., … & Speliotes, E. K. (2015). Genetic studies of body mass index yield new insights for obesity biology. *Nature*, 518(7538), 197-206.
  17. [18] Seale, P., Conroe, H. M., Estall, J., Kajimura, S., Frontini, A., Ishibashi, J., … & Spiegelman, B. M. (2011). Prdm16 determines the thermogenic program of subcutaneous white adipose tissue in mice. *The Journal of Clinical Investigation*, 121(1), 96-105.
  18. Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006). An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature*, 444(7122), 1027-1031.
  19. Goodarzi, M. O. (2018). Genetics of obesity: what genetic association studies have taught us about the biology of obesity and its complications. *The Lancet Diabetes & Endocrinology*, 6(3), 223-236.
  20. Khera, A. V., Chaffin, M., Wade, K. H., Zahid, S., Brancale, J., Xia, R., … & Kathiresan, S. (2019). Polygenic prediction of weight and obesity trajectories from birth to adulthood. *Cell*, 177(3), 587-596.
  21. Loos, R. J., & Yeo, G. S. (2022). The genetics of obesity: from discovery to biology. *Nature Reviews Genetics*, 23(2), 120-133.
  22. Matharu, N., Rattanasopha, S., Tamura, S., Maliskova, L., Wang, Y., Bernard, A., … & Ahituv, N. (2019). CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency. *Science*, 363(6424), eaau0629.
  23. Hidalgo-Cantabrana, C., Goh, Y. J., & Barrangou, R. (2019). Characterization and repurposing of type I and type II CRISPR-Cas systems in bacteria. *Journal of Molecular Biology*, 431(1), 21-33.
  24. World Health Organization. (2021). Obesity and overweight. [29] National Academies of Sciences, Engineering, and Medicine. (2017). Human Genome Editing: Science, Ethics, and Governance. Washington, DC: The National Academies Press.
  25. Shen, J., Zhang, C. J., Jiang, B., Chen, J., Song, J., Liu, Z., … & Miao, F. (2019). Artificial intelligence versus clinicians in disease diagnosis: Systematic review. *JMIR Medical Informatics*, 7(3), e10010.
  26. Claussnitzer, M., Cho, J. H., Collins, R., Cox, N. J., Dermitzakis, E. T., Hurles, M. E., … & McCarthy, M. I. (2020). A brief history of human disease genetics. *Nature*, 577(7789), 179-189.
  27. Flier, J. S. (2019). Starvation in the midst of plenty: reflections on the history and biology of insulin and leptin. *Endocrine Reviews*, 40(1), 1-16.

No Comments

Sorry, the comment form is closed at this time.